UnknownPHASE2, PHASE3NCT02042482

The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kaplan Medical Center
Principal Investigator
Kalman Kalman, MD
Kaplan Medical Center, Institute of hematology
Intervention
Coenzyme Q10U, L-carnitine(dietary_supplement)
Enrollment
40 enrolled
Eligibility
18-90 years · All sexes
Timeline
20132016

Study locations (1)

Collaborators

Weizmann Institute of Science

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02042482 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials